The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: A systematic review and meta-analysis of randomized, placebo-controlled trials

التفاصيل البيبلوغرافية
العنوان: The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: A systematic review and meta-analysis of randomized, placebo-controlled trials
المؤلفون: Naykky Singh-Ospina, Rene Rodriguez-Gutierrez, Juan P. Brito, Alejandro Salcido-Montenegro, Shalender Bhasin, Gabriela Spencer-Bonilla, Larry J. Prokop, Oscar J. Ponce, Neri Alejandro Álvarez-Villalobos, Valentina Serrano, Raed Benkhadra
بيانات النشر: Oxford University Press, 2018.
سنة النشر: 2018
مصطلحات موضوعية: medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, 030232 urology & nephrology, Context (language use), Placebo, Biochemistry, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Randomized controlled trial, law, Lower urinary tract symptoms, Internal medicine, medicine, Testosterone, Adverse effect, Replacement Therapy, 030219 obstetrics & reproductive medicine, purl.org/pe-repo/ocde/ford#3.02.18 [https], business.industry, Biochemistry (medical), medicine.disease, Hypogonadal Men, Systematic review, Meta-analysis, Relative risk, Systematic Review, business
الوصف: Context The efficacy and safety of testosterone replacement therapy (TRT) in hypogonadal men remain incompletely understood. Objective To conduct a systematic review and meta-analysis of randomized clinical trials (RCT) to determine the effects of TRT on patient-important outcomes and adverse events in hypogonadal men. Data sources We searched Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Database of Systematic Reviews, Ovid Cochrane Central Register of Controlled Trials, and Scopus from inception to March 2th, 2017. Study selection RCTs that assessed the efficacy and adverse events of TRT of at least 12 weeks compared with placebo in adult men with hypogonadism, defined by morning testosterone ≤300 ng/dL and at least one symptom or sign of hypogonadism. Data extraction Reviewers working independently and in duplicate assessed the quality of the trials and collected data on patient characteristics, interventions, and outcomes. Data synthesis We found 11 publications, reporting on 4 eligible trials (including 1,779 patients) at low risk of bias. Compared to placebo, TRT was associated with a small but significant increase in sexual desire or libido [standardized mean difference (SMD): 0.17, 95% CI 0.01, 0.34] (n=1383), erectile function [SMD: 0.16, 95% CI 0.06, 0.27] (n=1344), and sexual satisfaction [SMD: 0.16, 95% CI 0.01, 0.31] (n=676), but had no effect on energy or mood. TRT was associated with an increased risk of developing erythrocytosis [relative risk: 8.14, 95% CI: 1.87, 35.40] (n=1579) compared to placebo, but had no significant effect on lower urinary tract symptoms (LUTS). Conclusion In hypogonadal men TRT improves sexual desire, erectile function, and sexual satisfaction, however it increases the risk of erythrocytosis.
اللغة: English
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d23a7806f8c567c5838f5b01a4d71c1aTest
https://hdl.handle.net/20.500.12866/4189Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....d23a7806f8c567c5838f5b01a4d71c1a
قاعدة البيانات: OpenAIRE